Zoetis Stock Hits Day Low of $116.90 Amid Price Pressure

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 3.56% on March 18, 2026. The stock reached an intraday low of USD 116.90, reflecting ongoing challenges in the market. In terms of performance metrics, Zoetis has shown a year-to-date decline of 6.73%, while its one-year performance stands at a significant drop of 28.63%. Over the past month, the stock has decreased by 9.12%, indicating a consistent downward trend. Comparatively, the S&P 500 has also faced challenges, but its performance has been relatively better, with a one-year gain of 17.99%. Despite these declines, Zoetis maintains a strong operational foundation, highlighted by a high return on capital employed (ROCE) of 33.61% and a low debt-to-EBITDA ratio of 1.22 times, showcasing its ability to manage debt effectively. The company has reported positive results for the last six consecutive quarters, with net sales growing at an annual rate of 8.16%. However, the stock's performance has lagged behind the broader market, raising questions about its future trajectory.